Avalo Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 19
- Market Cap
- -
- Website
- http://www.avalotx.com
- Introduction
Avalo Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
Clinical Trials
11
Trial Phases
2 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Drug: AVTX-009 Regimen 1Drug: AVTX-009 Regimen 2Drug: Placebo
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Avalo Therapeutics, Inc.
- Target Recruit Count
- 222
- Registration Number
- NCT06603077
- Locations
- 🇺🇸
Clinical Site 1031, Bowling Green, Kentucky, United States
🇫🇷Clinical Site 1502, Lyon, Rhône, France
🇩🇪Clinical Site 1602, Muenster, Nordrhein-Westfalen, Germany
A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Avalo Therapeutics, Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT05288504
- Locations
- 🇺🇸
Tucson Neuroscience Research - M3, Wake Research, Tucson, Arizona, United States
🇺🇸Center For Clinical Trials of Sacramento, Sacramento, California, United States
🇺🇸Allergy and Asthma Medical Group of the Bay Area, Walnut Creek, California, United States
A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic Malformations
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- Avalo Therapeutics, Inc.
- Registration Number
- NCT04994002
- Locations
- 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Avalo Therapeutics, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT04671251
- Locations
- 🇺🇸
University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸James R. Berenson, MD., Inc., West Hollywood, California, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Avalo Therapeutics, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03169894
- Locations
- 🇺🇸
Sweet Hope Research Specialty, Inc., Hialeah, Florida, United States
🇺🇸Advanced Research Institute, Inc., New Port Richey, Florida, United States
🇺🇸Egleston Hospital, Atlanta, Georgia, United States
- Prev
- 1
- 2
- Next